鉴于哮喘的大表型多样性,本研究旨在使用特异性生物标志物来表征过敏性哮喘(AA)及其严重程度.从42名健康对照(HCs)和96名AA患者收集血液。与血细胞数量和功能相关的生物标志物:白细胞总数(TLCs),中性粒细胞,淋巴细胞,单核细胞,嗜酸性粒细胞,嗜碱性粒细胞,中性粒细胞与淋巴细胞比率(NLR),免疫球蛋白E(IgE),类胰蛋白酶和嗜酸性阳离子蛋白(ECP)以及重塑生物标志物(基质金属蛋白酶(MMP-9),(MMP-16),测量成纤维细胞生长因子(FGF-18)和(FGF-23)和α-骨骼肌肌动蛋白-1(ACTa-1)。在总白细胞水平较高的血液学参数中观察到显着差异,嗜酸性粒细胞,与HCs相比,AA组的嗜碱性粒细胞计数。疾病组的几种血清生物标志物(IgE,TP,ECP,MMP-9,MMP-16,FGF-18,FGF-23和ACTa-1)与HC相比。用力呼气容积1(FEV1)和用力肺活量(FVC)与ECP有很强的负相关性,IgE,和ACTa-1。FEV1与MMP-16和类胰蛋白酶呈负相关。AA患者的几种生物标志物水平较高,如MMP-9,MMP-16,FGF-18,FGF-23,IgE,胰蛋白酶,和ACTa-1。此外,IgE,胰蛋白酶,ACTa-1和MMP-16与AA的肺功能损害有关。这表明,当诊断和监测AA时,测量多种生物标志物在未来可能是有价值的。
Given asthma\'s large phenotypic diversity, the study was aimed to use specific biomarkers to characterize Allergic asthma (AA) and its severity. Blood was collected from 42 healthy controls (HCs) and 96 patients with AA. Biomarkers related to blood cell number and function: total leukocyte count (TLCs), neutrophil, lymphocyte, monocyte, eosinophil, basophil, neutrophil-to-lymphocyte ratio (NLR), immunoglobulin E (IgE), tryptase and eosinophilic cationic protein (ECP) as well as remodelling biomarkers (Matrix metalloproteinase (MMP-9), (MMP-16), Fibroblast growth factor (FGF-18) and (FGF-23) and alpha-skeletal muscle actin-1 (ACTa-1) were measured. Significant differences were observed in hematological parameters with higher levels of total leukocytes, eosinophil, and basophil counts in the AA group compared to HCs. The disease group also had significantly higher levels of several serum biomarkers (IgE, TPs, ECP, MMP-9, MMP-16, FGF-18, FGF-23, and ACTa-1) compared to HC. Forced expiratory volume 1 (FEV1) and forced vital capacity (FVC) had a strong negative correlation with ECP, IgE, and ACTa-1. FEV1 was negatively correlated with MMP-16 and tryptase. Patients with AA have higher levels of several biomarkers, such as MMP-9, MMP-16, FGF-18, FGF-23, IgE, tryptase, and ACTa-1. In addition, IgE, tryptase, ACTa-1, and MMP-16 are related to lung function impairment in AA. This indicates that measuring multiple biomarkers may be of value in the future when diagnosing and monitoring AA.